![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, July 06, 2022 9:44:51 PM
...I’ve argued in the past that TLD will set everything in motion. Now that it has, we’ll hear about FDA Breakthrough Therapy Designation (BTD) being granted to DCVax-L for GBM in about 2 months and a BLA submitted a short time after that. I base this on Amgen’s Sotorasib timeline that I reviewed in post 435926.
Quote:
________________________________________
Amgen PRs:
- TLD – 10.5.20
- BTD – 12.8.20
- FDA's RTOR Pilot Program submission – 12.8.20
- Sotorasib NDA submission to FDA – 12.16.20
- Sotorasib MAA submission to EMA – 12.22.20
- FDA's Project Orbis MAA submission to Australia, Brazil, Canada and the United Kingdom - Jan. 2021
- FDA Grants Sotorasib Priority Review Designation - 2.16.21
- FDA Approves LUMAKRAS™ (Sotorasib) -5.28.21
- EUROPEAN COMMISSION APPROVES LUMYKRAS® - 1.10.22
________________________________________
I would expect no less from NWBO in pushing DCVax-L through the approval process. Yes, they are a much smaller company w less resources but they’ve been sitting on TLD for probably over a year and may have started communication w the FDA much sooner than when we found out about TLD. And yes, we understand that communication w the MHRA has been ongoing and you’re probably right that we’ll get approval on the other side of the pond first but it won’t be by much. Exciting times ahead! - post 473353 (after the NYAS TLDish presentation)
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM